miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Interest Rates Are Forecast to Do Something They Haven't Done Since 2023, and It Could Trigger a Major Move in the Stock Market

View original at nasdaq.com
Interest Rates Are Forecast to Do Something They Haven't Done Since 2023, and It Could Trigger a Major Move in the Stock Market Key Points The Federal Reserve has cut interest rates six times since September 2024, after defeating the inflation crisis of 2022…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Federal Reserve targets a 2% annualized Consumer Price Index inflation rate.

    60% confidence
  • A $1,000 investment in Nvidia at the time of the April 15, 2005 Stock Advisor recommendation would be worth $1,345,714.

    60% confidence
  • A $1,000 investment in Netflix at the time of the December 17, 2004 Stock Advisor recommendation would be worth $481,589.

    60% confidence
  • When interest rates rise, debt repayments eat up a larger share of household budgets, reducing consumer spending and raising business credit costs, which hurts corporate earnings and stock prices.

    60% confidence
  • Higher oil prices raise the cost of any product requiring transportation by boat, plane, or truck, impacting consumers at gas pumps, grocery stores, and retailers.

    60% confidence
  • There is clear evidence that any significant increase in interest rates will likely disrupt the current bull run in the stock market.

    60% confidence
  • Oil prices are likely to remain elevated well into the second half of 2026 due to Middle East production cuts, which could stoke even more inflation.

    60% confidence
  • If the CPI continues to climb, Wall Street could start pricing in a rate hike before the end of 2026.

    60% confidence
  • There is a 57% probability of a Federal Reserve interest rate hike in January 2027, with odds increasing thereafter.

    60% confidence
  • Many of the biggest oil producers in the Middle East have slashed production because of Strait of Hormuz shipping restrictions, and it could take several months to bring it back online even if the war ended immediately.

    60% confidence
  • Stock Advisor has achieved a total average return of 993%, outperforming the S&P 500's 208% return.

    60% confidence
  • The overall increase in interest rates this time will probably be much smaller than in 2022-2023 because rates were coming off historic lows then.

    60% confidence
  • The Federal Reserve will start raising interest rates again, which could trigger a sharp decline in the stock market.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Interest Rates Are Forecast to Do Something They Haven't Done Since 2023, and It Could Trigger a Major Move in the Stock Market — Source | Via News | es.VIA.NEWS